206 related articles for article (PubMed ID: 24473683)
21. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
[TBL] [Abstract][Full Text] [Related]
23. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
25. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
26. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
27. An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells.
Miyata S; Urabe M; Gomi A; Nagai M; Yamaguchi T; Tsukahara T; Mizukami H; Kume A; Ozawa K; Watanabe E
Neurol Med Chir (Tokyo); 2013; 53(10):645-54. PubMed ID: 24077277
[TBL] [Abstract][Full Text] [Related]
28. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
Kang X; Chen R; Zhang J; Li G; Dai PG; Chen C; Wang HJ
Asian Pac J Cancer Prev; 2015; 16(8):3355-60. PubMed ID: 25921144
[TBL] [Abstract][Full Text] [Related]
29. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
[TBL] [Abstract][Full Text] [Related]
30. CXCR7 and CXCR4 Expressions in Infiltrative Astrocytomas and Their Interactions with HIF1α Expression and IDH1 Mutation.
Bianco AM; Uno M; Oba-Shinjo SM; Clara CA; de Almeida Galatro TF; Rosemberg S; Teixeira MJ; Nagahashi Marie SK
Pathol Oncol Res; 2015 Apr; 21(2):229-40. PubMed ID: 24970694
[TBL] [Abstract][Full Text] [Related]
31. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
32. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Tesileanu CMS; Vallentgoed WR; Sanson M; Taal W; Clement PM; Wick W; Brandes AA; Baurain JF; Chinot OL; Wheeler H; Gill S; Griffin M; Rogers L; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; de Vos F; Mulholland PJ; Taphoorn MJB; de Heer I; Hoogstrate Y; de Wit M; Boggiani L; Venneker S; Oosting J; Bovée JVMG; Erridge S; Vogelbaum MA; Nowak AK; Mason WP; Kros JM; Wesseling P; Aldape K; Jenkins RB; Dubbink HJ; Baumert B; Golfinopoulos V; Gorlia T; van den Bent M; French PJ
Acta Neuropathol; 2021 Jun; 141(6):945-957. PubMed ID: 33740099
[TBL] [Abstract][Full Text] [Related]
33. IDH1
Kim GH; Choi SY; Oh TI; Kan SY; Kang H; Lee S; Oh T; Ko HM; Lim JH
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151327
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
35. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
[TBL] [Abstract][Full Text] [Related]
36. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
[TBL] [Abstract][Full Text] [Related]
37. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
38. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
Odia Y; Varma H; Tsankova NM
Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
[TBL] [Abstract][Full Text] [Related]
39. Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma Grade III Sharing IDH1 R132H Mutation.
Tourne M; Tauziède-Espariat A; Dezamis E; Saffroy R; Dhermain F; Chrétien F; Varlet P
World Neurosurg; 2018 Aug; 116():316-321. PubMed ID: 29859360
[TBL] [Abstract][Full Text] [Related]
40. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
